VG Life Sciences Competitors and Similar CompaniesClear all
VG Life Sciences's competitors and similar companies include Epizyme, Syndax Pharmaceuticals, Outlook Therapeutics and Oncolytics Biotech.
 VG Life Sciences VG Life Sciences (VGLS, also known as SB Technology Holdings, formerly Viral Genetics) is a company that develops therapeutic and diagnostic pharmaceutical and medical products. |  Epizyme Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors. |  Syndax Pharmaceuticals Syndax Pharmaceuticals is a late-stage clinical development oncology company focused on overcoming the problem of resistance in cancer therapy. |  Outlook Therapeutics Outlook Therapeutics (formerly Oncobiologics) is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. |  Oncolytics Biotech Oncolytics Biotech is a company developing Pelareorep, an intravenously delivered immuno-oncolytic virus, used for the treatment of solid tumors and hematological malignancies. | |
Founding Date | Founding Date 1995 | Founding Date 2007 | Founding Date 2005 | Founding Date 2011 | Founding Date 1998 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations New York, US HQ | Locations Cambridge, US HQ | Locations Waltham, US HQ New York, US Waltham, US | Locations Woodbridge Township, US HQ | Locations Calgary, CA HQ Calgary, CA San Diego, US |
Employees | Employees 1 | Employees 20364% increase | Employees 358% decrease | Employees 1726% decrease | Employees 28 |
Valuation ($) | Valuation ($) 2.1 m | Valuation ($) 250.8 m | Valuation ($) 1.6 b | Valuation ($) 136.5 m | Valuation ($) 93.9 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $37.4m (FY, 2021) | Revenue (est.) $172.4m (FY, 2025) | Revenue (est.) $1.4m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $10.5m (FY, 2021) | Cost of goods N/A | Cost of goods $1.4m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $57.2k (FY, 2025) | Gross profit N/A |
Net income | Net income ($6.2m) (FY, 2014) | Net income ($251.1m) (FY, 2021) | Net income ($285.4m) (FY, 2025) | Net income ($62.4m) (FY, 2025) | Net income ($28.8m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 2.8m | Total funding raised $ 51.5m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 24m |
For sources of this data, please see the company profile
View Company Profiles
Epizyme
HQ
Cambridge, US
Employees
203
Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors.
View companySyndax Pharmaceuticals
HQ
Waltham, US
Employees
35↓ 8% decrease
Syndax Pharmaceuticals is a late-stage clinical development oncology company focused on overcoming the problem of resistance in cancer therapy.
View companyOutlook Therapeutics
HQ
Woodbridge Township, US
Employees
17↓ 26% decrease
Outlook Therapeutics (formerly Oncobiologics) is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics.
View companyOncolytics Biotech
HQ
Calgary, CA
Employees
28
Oncolytics Biotech is a company developing Pelareorep, an intravenously delivered immuno-oncolytic virus, used for the treatment of solid tumors and hematological malignancies.
View company